Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates
Portfolio Pulse from
Y-mAbs Therapeutics, Inc. (YMAB) reported a Q3 loss of $0.16 per share, missing the Zacks Consensus Estimate of a $0.14 loss. This is a slight improvement from the $0.18 loss per share a year ago.
November 08, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Y-mAbs Therapeutics reported a Q3 loss of $0.16 per share, missing the consensus estimate of $0.14. This may negatively impact the stock price in the short term.
The company reported a larger-than-expected loss per share, which typically leads to a negative reaction in the stock market. Although the loss is slightly better than last year's, missing estimates can still result in a short-term decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100